References

Epstein–Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation.

10.1182/blood.v71.5.1234.1234 · 1988 · External reference

10.1097/00007890-198804000-00011

10.1097/00007890-198804000-00011 · External reference

10.1200/jco.1995.13.4.961

10.1200/jco.1995.13.4.961 · External reference

10.1056/nejm198204153061506

10.1056/nejm198204153061506 · External reference

10.1016/0002-9343(89)90279-9

10.1016/0002-9343(89)90279-9 · External reference

10.1002/1097-0142(19931101)72:9<2782::aid-cncr2820720941>3.0.co;2-h

10.1002/1097-0142(19931101)72:9<2782::aid-cncr2820720941>3.0.co;2-h · External reference

10.1056/nejm198805193182013

10.1056/nejm198805193182013 · External reference

10.1016/s0140-6736(95)91150-2

10.1016/s0140-6736(95)91150-2 · External reference

Anti‐B‐cell monoclonal antibody treatment of severe posttransplant B‐lymphoproliferative disorder: prognostic factors and long‐term outcome.

10.1182/blood.v92.9.3137 · 1998 · External reference

10.1056/nejm199105233242102

10.1056/nejm199105233242102 · External reference

10.1172/jci115971

10.1172/jci115971 · External reference

Successful treatment of post‐transplant lymphoproliferative disorder with renal graft preservation by monoclonal antibody therapy.

1996 · External reference

10.1016/s0140-6736(05)70493-1

10.1016/s0140-6736(05)70493-1 · External reference

CD20 monoclonal antibody (rituximab) for therapy of Epstein–Barr virus lymphoma after hemopoietic stem‐cell transplantation.

10.1182/blood.v95.4.1502.004k40_1502_1505 · 2000 · External reference

Treatment of B‐lymphoproliferative disorder by a monoclonal anti‐interleukine‐6 antibody in twelve patients: a multicenter phase I–II clinical trial.

External reference

Role of IL‐6 in promoting growth of human EBV‐induced B‐cell tumors in severe combined immunodeficient mice.

10.4049/jimmunol.152.11.5361 · 1994 · External reference